ArticleJournal of gastrointestinal oncology2022

Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study.

Jinyu Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.